+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recombinant Drugs to 2020

  • ID: 4058177
  • Report
  • Region: Global
  • Greystone Associates
1 of 2
The Pace of this Growth is Encouraging Suppliers to View Competitors in New Ways

In recent years, the number of recombinant drugs - including engineered biological drugs in development - has increased significantly. The pace of this growth is encouraging suppliers to view competitors in new ways. Cooperation between and among drug developers and drug producers is occurring much earlier in the drug development cycle, allowing participants to improve supply chains and time-to-market.

The result is a rapidly growing market sector that is changing disease therapeutics on a global scale. This report examines FDA and EMA-approved biological drugs and their position and potential in a dozen major disease segments - markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors.

Recombinant Drugs to 2020 - What You Will Learn

  • What are the currently approved biological drugs; their host system, indication(s)?
  • What are the key market segments for biological drugs; what is the competitive picture for each segment?
  • What are the drug classes, therapeutic classes and market segments that comprise the global market for biological drugs?
  • What are the supply chain dynamics of biological drug sourcing and commercialization?
  • What is the revenue picture for each drug/class? What will it look like in 2020?
  • Who are the leading biological drug suppliers, and what are the key collaborations in the sourcing cycle?
  • What is the drug landscape for key market segments? What is the market share? What is the size?

Report Value Chain – Who Should Read this Report


  • Drug Developers
  • Device Suppliers
  • CMOs
  • Components/APIs
  • Testing/Validation
  • Clinical Trial Mgmt


  • Pharma Managers
  • Biotech Managers
  • Drug Marketers
  • Industry Strategists
  • Financial Analysts
  • Management Consultant


  • Clinical Managers
  • Drug Distributors
  • Pharma Regulators
  • FDA Consultants
  • Managed Care Managers
Note: Product cover images may vary from those shown
2 of 2

1. Executive Summary

2. Recombinant Drug Market Dynamics

3. The Biological Therapeutics Market Space

  • Clinical Trials and Drug Approvals
  • The Competitive Landscape
  • Demographics, Managed Care and Growth
  • Demand Drivers and Treatment Factors
  • Disease Type and Severity
  • Self-Treatment
  • Administration & Packaging
  • Reimbursement & Managed Care
  • Recombinant Drug Sourcing
  • Sourcing by Company
  • Sourcing by Country/Region
  • Sourcing Relationships

4.Product Technology Factors

  • Therapeutic Targets
  • Receptors, Inhibitors and Blockers
  • PEGylated Formulations

5. Recombinant Drug Analysis

  • FDA-Approved Drugs
  • EU-Approved Drugs
  • Approved Biosimilars

6. Recombinant Drug Market Analysis

  • Antihemophilic Factors
  • Antineoplastics
  • Colony Stimulating Factors
  • Enzyme Therapy
  • Erythropoiesis-stimulating Proteins
  • Follicle Stimulating Hormones
  • Glycemic Control
  • Growth Hormones
  • Non-TNF Immune Modulators
  • TNF Inhibitors
  • VEGF Inhibitors

7. Market Factors

  • Regulatory Issues
  • Biosimilars
  • Healthcare Economics

8. Company Profiles

Note: Product cover images may vary from those shown
3 of 2